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COPD is a disease of enormous and growing global burden1, ranked third as a global cause of death by the World Health Organization in 2016 (ref. 2). Environmental risk factors, 
predominately cigarette smoking, account for a large fraction of 
disease risk, but there is considerable variability in COPD suscepti-
bility among individuals with similar smoking exposure. Studies in 
families and in populations have demonstrated that genetic factors 
account for a substantial fraction of disease susceptibility. Similarly 
to other adult-onset complex diseases, common variants are likely 
to account for the majority of population genetic susceptibility3,4. 
Our previous efforts have identified 22 genome-wide-significant 
loci5. Expanding the number of loci can lead to new insights into 
disease pathogenesis, not only through discovery of new biology at 
individual loci6,7 but also across loci via identification of functional 
links and specific cell types and phenotypes5.
We performed a genome-wide association study (GWAS) com-
bining previously described studies from the International COPD 
Genetics Consortium (ICGC)5 with additional subjects from the UK 
Biobank8, a population-based study of several hundred thousand 
subjects with lung function and cigarette smoking assessment. We 
determined, through bioinformatic and computational analysis, the 
likely set of variants, genes, cell types, and biological pathways impli-
cated by these associations. Finally, we assessed our genetic findings 
for relevance to COPD-specific, respiratory, and other phenotypes.
Results
Genome-wide association study of COPD. We included a total 
of 257,811 individuals from 25 studies in the analysis, including 
studies from ICGC and UK Biobank (Fig. 1). We defined COPD 
on the basis of prebronchodilator spirometry according to modified 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
criteria for moderate to very severe airflow limitation9, as done pre-
viously5. This definition resulted in 35,735 cases and 222,076 con-
trols (Supplementary Table 1). We tested association of COPD and 
6,224,355 variants in a meta-analysis of 25 studies, by using a fixed-
effects model. We found no evidence of confounding by population 
substructure using the linkage disequilibrium score regression10 
(LDSC) intercept (1.0377, standard error (s.e.) = 0.0094).
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Chronic obstructive pulmonary disease (COPD) is the leading cause of respiratory mortality worldwide. Genetic risk loci provide 
new insights into disease pathogenesis. We performed a genome-wide association study in 35,735 cases and 222,076 controls 
from the UK Biobank and additional studies from the International COPD Genetics Consortium. We identified 82 loci associated 
with P < 5 × 10−8; 47 of these were previously described in association with either COPD or population-based measures of lung 
function. Of the remaining 35 new loci, 13 were associated with lung function in 79,055 individuals from the SpiroMeta consor-
tium. Using gene expression and regulation data, we identified functional enrichment of COPD risk loci in lung tissue, smooth 
muscle, and several lung cell types. We found 14 COPD loci shared with either asthma or pulmonary fibrosis. COPD genetic risk 
loci clustered into groups based on associations with quantitative imaging features and comorbidities. Our analyses provide 
further support for the genetic susceptibility and heterogeneity of COPD.
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We identified 82 loci (defined by using 2-Mb windows) at 
genome-wide significance (P < 5 × 10−8) (Figs. 1 and 2, and 
Supplementary Figs. 1 and 2). Forty-seven of the 82 loci were 
previously described as genome-wide significant in COPD5,11 or 
lung function12–20 (Supplementary Table 2), thus leaving 35 new 
loci (Table 1) at the time of analysis. We then sought to replicate 
these loci. Given the strong genetic correlation between popula-
tion-based measures of lung function and COPD, we tested the 
lead variant at each locus for association with forced expiratory 
volume in 1 s (FEV1) or FEV1/forced vital capacity (FVC) in 
79,055 individuals from SpiroMeta21 (Supplementary Table 3). 
We identified 13 loci—C1orf87, DENND2D, DDX1, SLMAP, BTC, 
FGF18, CITED2, ITGB8, STN1, ARNTL, SERP2, DTWD1, and 
ADAMTSL3—that replicated by using a Bonferroni correction 
for one-sided P value (P < 0.05/35; Table 1). Although they did 
not meet the strict Bonferroni threshold, 14 additional new loci 
were nominally significant in SpiroMeta (consistent direction of 
effect and one-sided P < 0.05): ASAP2, EML4, VGLL4, ADCY5, 
HSPA4, CCDC69, RREB1, ID4, IER3, RFX6, MFHAS1, COL15A1, 
TEPP, and THRA (Table 1), and all 82 loci showed a consistent 
direction of effect in COPD and either FEV1 or FEV1/FVC ratio 
in SpiroMeta (Table 1 and Supplementary Table 2). We note that 9 
of our 35 new loci were recently described in a contemporaneous 
analysis of lung function in UK Biobank21. None of the new loci 
appeared to be explained by cigarette smoking, and variant effect 
sizes in ever- and never-smokers and including and excluding self-
reported asthmatics were similar (Supplementary Note). In addi-
tion, we found no significant differences in variant effects by sex 
(Supplementary Note). Including all 82 genome-wide-significant 
variants, we explained up to 7.0% of the phenotypic variance on 
the liability scale, using a 10% prevalence for COPD, acknowledg-
ing that these effects are likely to be overestimated in the discovery 
sample. This represents up to a 48% increase in COPD phenotypic 
variance explained by genetic loci, as compared with the 4.7% 
explained by the 22 loci reported in a recent GWAS of COPD5.
Identification of secondary association signals. We used approxi-
mate conditional and joint analysis22 to find secondary signals at 
each of the 82 genome-wide-significant loci. We found 82 secondary 
signals at 50 loci, thus resulting in a total of 164 independent asso-
ciations at 82 loci (Supplementary Table 4). Of the 50 loci contain-
ing secondary associations, 33 were at loci previously described for 
COPD or lung function, and 6 were at Bonferroni-replicated new 
loci. Of the 82 secondary associations, 20 reached genome-wide 
significance (P < 5 × 10−8) (Supplementary Table 4). Of the 61 new 
(not previously described in COPD or lung function) indepen-
dent associations, 21 reached a region-wise Bonferroni-corrected 
significance threshold (one-sided P < 0.05/new independent 
association(s) at each locus) in unconditioned associations from 
SpiroMeta (Methods and Supplementary Table 4).
Tissues and specific cell types. In determining the tissue in 
which COPD genetic variants function to increase COPD risk, 
the lung is the obvious tissue to consider. However, COPD is 
a systemic disease23,24, and within the lung, the cell types collec-
tively contributing to disease pathogenesis are largely unknown. 
Furthermore, available databases include nonlung cell types, such 
as smooth muscle in the gastrointestinal (GI) tract, that are rel-
evant to lung biology. To identify putative causal tissues and cell 
types, we assessed heritability enrichment by using integrated 
genome annotations at the single-tissue level25 and tissue-specific 
epigenomic marks26. Lung tissue showed the highest enrichment 
(enrichment = 9.25, P = 1.36 × 10−9), as previously described, 
although significant enrichment was also seen in the heart (enrich-
ment = 6.85, P = 3.83 × 10−8) and the GI tract (enrichment = 5.53, 
P = 6.45 × 10−11). In an analysis of enriched epigenomic marks, 
the most significant enrichment was in fetal lung and GI smooth 
muscle DNase-hypersensitivity sites (DHSs) (P = 6.75 × 10−8) and 
H3K4me1 (P = 7.31 × 10−7) (Supplementary Table 5). To identify 
the source of association within lung tissue, we tested for herita-
bility enrichment by using single-cell chromatin accessibility27 
(ATAC-seq) and gene expression (RNA-seq) data from human28,29 
and mouse30 lung (Supplementary Table 5). Using LD score regres-
sion in mouse ATAC-seq data, we found enrichment of chromatin 
accessibility in several cell types, including endothelial cells (most 
significant) as well as type 1 and type 2 alveolar cells (with the latter 
among the tissues with the highest fold enrichment; Supplementary 
Table 5b). Results from using LD score regression31 or SNPsea32 on 
single-cell RNA-seq data varied, with nominal P values for genes 
expressed in type 2 alveolar cells, basal-like cells, club cells, fibro-
blasts, and smooth muscle cells (Supplementary Table 5c,d).
Fine-mapping of associated loci. To identify the most likely 
causal variants at each locus, we performed fine-mapping using 
Bayesian credible sets33. Including 160 potential primary and sec-
ondary association signals (excluding four variants in the major 
histocompatibility complex (MHC) region), 61 independent signals 
had a 99%-credible set with fewer than 50 variants; 34 signals had 
credible sets with fewer than 20 variants (Supplementary Fig. 3). 
Eighteen loci had a single variant with a posterior probability of 
driving association (PPA) greater than 60%, including the NPNT 
(4q24) locus, where the association could be fine-mapped to a 
single intronic variant, rs34712979 (NC_000004.11:g.106819053
G>A; Supplementary Note and Supplementary Table 6). Most sets 
included variants that overlapped genic enhancers in lung-related 
cell types (for example, fetal lung fibroblasts, fetal lung, and adult 
lung fibroblasts) and were predicted to alter transcription-factor-
binding motifs (Supplementary Table 6). Of the 61 credible sets with 
fewer than 50 variants, 8 sets contained at least one deleterious vari-
ant. These deleterious variants included (i) missense variants affect-
ing TNS1, RIN3, ADGRG6, ADAM19, ATP13A2, BTC, and CRLF3 
and (ii) a splice donor variant affecting a long intergenic noncoding 
RNA (lincRNA), AP003059.2.
Candidate target genes. In most cases, the closest gene to a lead 
SNP will not be the gene most likely to be the causal or effector gene 
for disease-associated variants34–36. Thus, to identify the potential 
effector (‘target’) genes underlying the genetic associations, we inte-
grated additional molecular information including gene expression, 
gene regulation (open chromatin and methylation data), chromatin 
UK Biobank
ARIC
…
Meta-analysis of COPD in 25 studies
(35,735 cases and 222,076 controls)
Associations at known loci
for COPD or lung function
Bonferroni-replicated loci
Lookup in SpiroMeta
(FEV1 or FEV1/FVC)
One-sided P < 0.05
14 loci
One-sided P < 0.05/new loci
13 loci
Nominally replicated loci
47 loci
35 loci
P < 5 × 10–8 82 loci
New loci
Fig. 1 | Study design. COPD, chronic obstructive pulmonary disease; 
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ARIC, 
Atherosclerosis Risk in Communities.
NATuRE GENETICS | VOL 51 | MARCH 2019 | 494–505 | www.nature.com/naturegenetics 495
Articles Nature GeNetics
Ta
bl
e 
1 |
 M
et
a-
an
al
ys
is
 re
su
lts
 s
ho
w
in
g 
35
 lo
ci
 n
ew
ly
 a
ss
oc
ia
te
d 
w
ith
 C
O
PD
 a
nd
 lu
ng
 fu
nc
tio
n
rs
ID
H
G
V
S 
na
m
e
Cl
os
es
t g
en
e
Lo
cu
s
Ri
sk
/a
lt.
 
al
le
le
RA
F
u
K 
Bi
ob
an
k
IC
G
C 
co
ho
rt
s
O
ve
ra
ll 
m
et
a-
an
al
ys
is
Sp
iro
M
et
a 
FE
V
1
Sp
iro
M
et
a 
FE
V
1/
FV
C
O
R
95
%
 C
I
P 
O
R
95
%
 C
I
P
O
R
95
%
 C
I
P
β
P
β
P
Si
gn
ifi
ca
nt
 in
 S
pi
ro
M
et
a 
us
in
g 
Bo
nf
er
ro
ni
 c
or
re
ct
io
n 
fo
r n
ew
 lo
ci
 (o
ne
-s
id
ed
 P
 <
 0
.0
5/
35
)
rs
72
67
34
19
N
C
_0
00
00
1.1
0:
g.
60
91
31
43
C
>T
C1
or
f8
7
1p
32
.1
T/
C
0.
05
1.1
3
1.0
7–
1.1
8
2.
0 
× 
10
–6
1.1
9
1.0
8–
1.3
1
2.
9 
× 
10
–4
1.1
4
1.0
9–
1.1
9
4.
0 
× 
10
–9
–2
 ×
 10
–2
1.3
 ×
 10
–1
–4
.7
 ×
 10
–2
3.
0 
× 
10
–4
rs
62
96
19
N
C
_0
00
00
1.1
0:
g.
11
17
38
10
8C
>T
D
EN
N
D
2D
1p
13
.3
T/
C
0.
20
1.0
8
1.0
5–
1.1
1
7.
5 
× 
10
–8
1.1
0
1.0
4–
1.1
6
8.
2 
× 
10
–4
1.0
8
1.0
6–
1.1
1
2.
9 
× 
10
–1
0
–5
.4
 ×
 10
–3
4.
6 
× 
10
–1
–2
.4
 ×
 10
–2
9.
3 
× 
10
–4
rs
10
92
93
86
N
C
_0
00
00
2.
11
:g
.15
90
61
79
C
>T
D
DX
1
2p
24
.3
C
/T
0.
49
1.0
6
1.0
3–
1.0
8
1.2
 ×
 10
–6
1.0
7
1.0
3–
1.1
2
1.8
 ×
 10
–3
1.0
6
1.0
4–
1.0
8
9.
1 ×
 10
–9
–2
.5
 ×
 10
–2
3.
1 ×
 10
–6
–2
.4
 ×
 10
–2
7.1
 ×
 10
–6
rs
62
25
90
26
N
C
_0
00
00
3.
11
:g
.5
77
46
51
5C
>T
SL
M
A
P
3p
14
.3
C
/T
0.
75
1.0
7
1.0
4–
1.0
9
1.8
 ×
 10
–6
1.0
7
1.0
2–
1.1
2
3.
8 
× 
10
–3
1.0
7
1.0
4–
1.0
9
2.
4 
× 
10
–8
–2
.7
 ×
 10
–2
3.
3 
× 
10
–5
–1
.2
 ×
 10
–2
6.
4 
× 
10
–2
rs
45
85
38
0
N
C
_0
00
00
4.
11
:g
.7
56
73
36
3G
>A
BT
C
4q
13
.3
G
/A
0.
74
1.0
7
1.0
4–
1.1
0
1.2
 ×
 10
–7
1.0
6
1.0
2–
1.1
1
8.
1 ×
 10
–3
1.0
7
1.0
5–
1.0
9
3.
4 
× 
10
–9
–2
.3
 ×
 10
–2
3.
7 
× 
10
–4
–2
.0
 ×
 10
–2
1.3
 ×
 10
–3
rs
12
51
91
65
N
C
_0
00
00
5.
9:
g.
17
09
01
58
6A
>T
FG
F1
8
5q
35
.1
A
/T
0.
38
1.0
8
1.0
5–
1.1
0
2.
7 
× 
10
–1
0
1.0
2
0.
97
–1
.0
8
4.
0 
× 
10
–1
1.0
7
1.0
5–
1.0
9
1.1
 ×
 10
–9
–1
.7
 ×
 10
–2
6.
5 
× 
10
–3
–3
.1 
× 
10
–2
2.
4 
× 
10
–7
rs
64
66
95
N
C
_0
00
00
6.
11
:g
.14
02
80
39
8T
>C
CI
TE
D
2
6q
24
.1
C
/T
0.
24
1.0
7
1.0
5–
1.1
0
3.
0 
× 
10
–8
1.0
9
1.0
4–
1.1
4
3.
4 
× 
10
–4
1.0
8
1.0
5–
1.1
0
4.
6 
× 
10
–1
1
–2
.2
 ×
 10
–2
5.
6 
× 
10
–4
2.
1 ×
 10
–3
7.
5 
× 
10
–1
rs
20
40
73
2
N
C
_0
00
00
7.1
3:
g.
20
41
81
34
C
>T
IT
GB
8
7p
21
.1
C
/T
0.
58
1.0
7
1.0
5–
1.0
9
5.
2 
× 
10
–9
1.0
3
0.
99
–1
.0
7
1.7
 ×
 10
–1
1.0
6
1.0
4–
1.0
8
6.
9 
× 
10
–9
–1
.6
 ×
 10
–2
1.8
 ×
 10
–3
–1
.3
 ×
 10
–2
1.0
 ×
 10
–2
rs
15
70
22
1
N
C
_0
00
01
0.
10
:g
.10
56
56
87
4G
>A
ST
N
1
10
q2
4.
33
A
/G
0.
35
1.0
6
1.0
3–
1.0
8
3.
5 
× 
10
–6
1.0
7
1.0
3–
1.1
2
1.4
 ×
 10
–3
1.0
6
1.0
4–
1.0
8
2.
2 
× 
10
–8
–1
.9
 ×
 10
–2
9.
5 
× 
10
–4
–1
.2
 ×
 10
–2
3.
9 
× 
10
–2
rs
47
57
11
8
N
C
_0
00
01
1.9
:g
.13
17
12
36
C
>T
A
RN
TL
11
p1
5.
2
T/
C
0.
54
1.0
7
1.0
4–
1.0
9
1.1
 ×
 10
–8
1.0
4
1.0
0–
1.0
8
7.
3 
× 
10
–2
1.0
6
1.0
4–
1.0
8
3.
8 
× 
10
–9
–5
.7
 ×
 10
–3
2.
8 
× 
10
–1
–1
.6
 ×
 10
–2
2.
2 
× 
10
–3
rs
95
25
92
7
N
C
_0
00
01
3.
10
:g
.4
48
42
50
3G
>A
SE
RP
2
13
q1
4.
11
G
/A
0.
19
1.0
7
1.0
4–
1.1
0
2.
9 
× 
10
–6
1.1
0
1.0
5–
1.1
6
1.4
 ×
 10
–4
1.0
8
1.0
5–
1.1
0
2.
8 
× 
10
–9
–1
.5
 ×
 10
–2
2.
2 
× 
10
–2
–2
.1 
× 
10
–2
2.
2 
× 
10
–3
rs
72
73
11
49
N
C
_0
00
01
5.
9:
g.
49
98
47
10
G
>C
DT
W
D
1
15
q2
1.2
G
/C
0.
91
1.1
2
1.0
7–
1.1
7
8.
9 
× 
10
–7
1.1
2
1.0
4–
1.2
0
2.
6 
× 
10
–3
1.1
2
1.0
8–
1.1
6
8.
3 
× 
10
–9
–5
.2
 ×
 10
–2
7.9
 ×
 10
–7
–3
.5
 ×
 10
–2
9.
0 
× 
10
–4
rs
10
15
23
00
N
C
_0
00
01
5.
9:
g.
84
39
29
07
G
>A
A
DA
M
TS
L3
15
q2
5.
2
G
/A
0.
23
1.0
9
1.0
6–
1.1
1
2.
4 
× 
10
–1
0
1.0
8
1.0
2–
1.1
3
4.
7 
× 
10
–3
1.0
8
1.0
6–
1.1
1
4.
2 
× 
10
–1
2
–1
.2
 ×
 10
–2
6.
4 
× 
10
–2
–2
.1 
× 
10
–2
1.5
 ×
 10
–3
N
om
in
al
ly
 s
ig
ni
fic
an
t i
n 
Sp
iro
M
et
a 
(o
ne
-s
id
ed
 P
 <
 0
.0
5)
rs
95
52
77
N
C
_0
00
00
2.
11
:g
.9
29
03
57
C
>T
A
SA
P2
2p
25
.1
T/
C
0.
61
1.0
8
1.0
5–
1.1
0
2.
7 
× 
10
–1
0
1.0
4
0.
99
–1
.0
8
8.
6 
× 
10
–2
1.0
7
1.0
5–
1.0
9
1.9
 ×
 10
–1
0
–2
.9
 ×
 10
–4
9.
6 
× 
10
–1
–1
.1 
× 
10
–2
3.
3 
× 
10
–2
rs
12
46
69
81
N
C
_0
00
00
2.
11
:g
.4
24
33
24
7C
>T
EM
L4
2p
21
C
/T
0.
73
1.0
6
1.0
3–
1.0
8
8.
1 ×
 10
–6
1.0
8
1.0
3–
1.1
3
1.2
 ×
 10
–3
1.0
6
1.0
4–
1.0
9
4.
9 
× 
10
–8
–1
.2
 ×
 10
–2
4.
4 
× 
10
–2
–1
.1 
× 
10
–2
6.
4 
× 
10
–2
rs
24
42
77
6
N
C
_0
00
00
3.
11
:g
.11
64
06
01
G
>A
VG
LL
4
3p
25
.3
G
/A
0.
15
1.0
9
1.0
6–
1.1
3
5.
7 
× 
10
–8
1.1
0
1.0
4–
1.1
6
8.
9 
× 
10
–4
1.0
9
1.0
6–
1.1
2
2.
0 
× 
10
–1
0
–1
.4
 ×
 10
–2
6.
4 
× 
10
–2
–1
.1 
× 
10
–2
1.3
 ×
 10
–1
rs
40
93
84
0
N
C
_0
00
00
3.
11
:g
.12
30
77
04
2T
>A
A
D
CY
5
3q
21
.1
A
/T
0.
47
1.0
7
1.0
5–
1.0
9
1.6
 ×
 10
–9
1.0
4
1.0
0–
1.0
9
4.
8 
× 
10
–2
1.0
6
1.0
4–
1.0
8
3.
9 
× 
10
–1
0
–9
.5
 ×
 10
–3
8.
5 
× 
10
–2
–4
.9
 ×
 10
–3
3.
8 
× 
10
–1
rs
62
37
52
46
N
C
_0
00
00
5.
9:
g.
13
24
39
01
0T
>A
H
SP
A
4
5q
31
.1
A
/T
0.
26
1.0
8
1.0
5–
1.1
0
9.
6 
× 
10
–9
1.0
3
0.
98
–1
.0
8
2.
7 
× 
10
–1
1.0
6
1.0
4–
1.0
9
2.
2 
× 
10
–8
–1
.5
 ×
 10
–2
1.3
 ×
 10
–2
–7
.5
 ×
 10
–3
2.
2 
× 
10
–1
rs
97
94
53
N
C
_0
00
00
5.
9:
g.
15
05
95
07
3A
>G
CC
D
C6
9
5q
33
.1
G
/A
0.
34
1.0
7
1.0
5–
1.1
0
1.6
 ×
 10
–9
1.0
2
0.
97
–1
.0
6
5.
1 ×
 10
–1
1.0
6
1.0
4–
1.0
8
1.4
 ×
 10
–8
–1
.1 
× 
10
–2
7.
2 
× 
10
–2
–2
.7
 ×
 10
–3
6.
4 
× 
10
–1
rs
13
34
57
6
N
C
_0
00
00
6.
11
:g
.7
21
18
18
G
>A
RR
EB
1
6p
24
.3
A
/G
0.
42
1.0
7
1.0
5–
1.0
9
4.
2 
× 
10
–9
1.0
2
0.
99
–1
.0
6
2.
2 
× 
10
–1
1.0
6
1.0
4–
1.0
8
1.2
 ×
 10
–8
2.
1 ×
 10
–3
6.
9 
× 
10
–1
–1
.2
 ×
 10
–2
2.
9 
× 
10
–2
rs
93
50
19
1
N
C
_0
00
00
6.
11
:g
.19
84
26
61
C
>T
ID
4
6p
22
.3
T/
C
0.
85
1.1
1
1.0
8–
1.1
5
6.
2 
× 
10
–1
2
1.1
4
1.0
5–
1.2
3
1.9
 ×
 10
–3
1.1
2
1.0
9–
1.1
5
5.
1 ×
 10
–1
4
–1
.6
 ×
 10
–2
4.
9 
× 
10
–2
–1
.1 
× 
10
–2
1.5
 ×
 10
–1
rs
22
84
17
4
N
C
_0
00
00
6.
11
:g
.3
07
13
58
0T
>C
IE
R3
6p
21
.3
3
C
/T
0.
22
1.1
2
1.1
0–
1.1
5
3.
4 
× 
10
–1
9
1.1
2
1.0
5–
1.2
1
1.5
 ×
 10
–3
1.1
2
1.1
0–
1.1
5
2.
1 ×
 10
–2
1
–1
.4
 ×
 10
–2
5.
2 
× 
10
–2
–1
.6
 ×
 10
–2
3.
0 
× 
10
–2
rs
67
46
21
N
C
_0
00
00
6.
11
:g
.11
72
57
01
8T
>C
RF
X6
6q
22
.1
C
/T
0.
32
1.0
6
1.0
3–
1.0
8
1.3
 ×
 10
–6
1.0
7
1.0
3–
1.1
2
1.4
 ×
 10
–3
1.0
6
1.0
4–
1.0
8
7.
6 
× 
10
–9
–1
.2
 ×
 10
–2
3.
6 
× 
10
–2
–1
.1 
× 
10
–2
6.
9 
× 
10
–2
rs
93
29
17
0
N
C
_0
00
00
8.
10
:g
.8
69
76
58
C
>G
M
FH
A
S1
8p
23
.1
C
/G
0.
86
1.1
0
1.0
6–
1.1
4
2.
0 
× 
10
–8
1.0
9
1.0
3–
1.1
5
4.
9 
× 
10
–3
1.1
0
1.0
7–
1.1
3
3.
6 
× 
10
–1
0
–1
.5
 ×
 10
–2
4.
6 
× 
10
–2
–1
.4
 ×
 10
–2
6.
5 
× 
10
–2
rs
10
76
05
80
N
C
_0
00
00
9.
11
:g
.10
16
61
65
0G
>A
CO
L1
5A
1
9q
22
.3
3
G
/A
0.
71
1.0
8
1.0
6–
1.1
1
1.6
 ×
 10
–1
0
1.0
4
0.
99
–1
.0
9
1.1
 ×
 10
–1
1.0
7
1.0
5–
1.1
0
1.2
 ×
 10
–1
0
–1
.5
 ×
 10
–2
1.5
 ×
 10
–2
–1
.5
 ×
 10
–2
1.4
 ×
 10
–2
rs
80
44
65
7
N
C
_0
00
01
6.
9:
g.
58
02
26
25
G
>A
TE
PP
16
q2
1
G
/A
0.
90
1.1
2
1.0
7–
1.1
6
1.7
 ×
 10
–7
1.0
9
1.0
1–
1.1
7
1.8
 ×
 10
–2
1.1
1
1.0
7–
1.1
5
1.1
 ×
 10
–8
–1
.6
 ×
 10
–2
9.
9 
× 
10
–2
–2
.1 
× 
10
–2
2.
8 
× 
10
–2
rs
62
06
52
16
N
C
_0
00
01
7.1
0:
g.
38
21
87
73
G
>A
TH
RA
17
q2
1.1
A
/G
0.
42
1.0
6
1.0
4–
1.0
9
1.2
 ×
 10
–7
1.0
6
1.0
1–
1.1
0
2.
2 
× 
10
–2
1.0
6
1.0
4–
1.0
8
8.
1 ×
 10
–9
–9
.5
 ×
 10
–3
7.
8 
× 
10
–2
–1
.4
 ×
 10
–3
8.
0 
× 
10
–1
N
ot
 s
ig
ni
fic
an
t (
di
re
ct
io
na
lly
 c
on
si
st
en
t o
nl
y)
rs
46
60
86
1
N
C
_0
00
00
1.1
0:
g.
45
94
66
36
G
>T
TE
SK
2
1p
34
.1
G
/T
0.
57
1.0
5
1.0
3–
1.0
8
7.
2 
× 
10
–6
1.0
7
1.0
3–
1.1
2
1.2
 ×
 10
–3
1.0
6
1.0
4–
1.0
8
4.
4 
× 
10
–8
–5
.5
 ×
 10
–3
3.
0 
× 
10
–1
–4
.4
 ×
 10
–3
4.
1 ×
 10
–1
rs
76
50
60
2
N
C
_0
00
00
3.
11
:g
.14
11
47
41
4T
>C
ZB
TB
38
3q
23
C
/T
0.
45
1.0
7
1.0
4–
1.0
9
6.
7 
× 
10
–9
1.0
1
0.
97
–1
.0
6
5.
1 ×
 10
–1
1.0
6
1.0
4–
1.0
8
4.
9 
× 
10
–8
1.1
 ×
 10
–3
8.
4 
× 
10
–1
–5
.5
 ×
 10
–3
3.
2 
× 
10
–1
rs
34
65
1
N
C
_0
00
00
5.
9:
g.
72
14
40
05
C
>T
TN
PO
1
5q
13
.2
C
/T
0.
08
1.1
0
1.0
6–
1.1
5
7.
5 
× 
10
–7
1.1
2
1.0
2–
1.2
2
1.2
 ×
 10
–2
1.1
1
1.0
7–
1.1
5
3.
0 
× 
10
–8
–3
.2
 ×
 10
–3
7.
6 
× 
10
–1
3.
4 
× 
10
-2
7.
5 
× 
10
–1
rs
79
85
65
N
C
_0
00
00
7.1
3:
g.
27
52
15
2G
>A
A
M
Z1
7p
22
.3
G
/A
0.
71
1.0
9
1.0
6–
1.1
1
2.
8 
× 
10
–1
1
1.0
0
0.
95
–1
.0
5
8.
8 
× 
10
–1
1.0
7
1.0
4–
1.0
9
3.
9 
× 
10
–9
–9
.0
 ×
 10
–3
1.2
 ×
 10
–1
–2
.9
 ×
 10
–3
6.
1 ×
 10
–1
rs
78
66
93
9
N
C
_0
00
00
9.
11
:g
.8
51
26
16
3T
>C
RA
SE
F
9q
21
.3
2
C
/T
0.
33
1.0
6
1.0
3–
1.0
8
1.3
 ×
 10
–6
1.0
7
1.0
2–
1.1
2
3.
8 
× 
10
–3
1.0
6
1.0
4–
1.0
8
1.7
 ×
 10
–8
–6
.9
 ×
 10
–3
2.
5 
× 
10
–1
–9
.5
 ×
 10
–3
1.1
 ×
 10
–1
rs
79
58
94
5
N
C
_0
00
01
2.
11
:g
.11
59
47
90
1A
>G
M
ED
13
L
12
q2
4.
21
G
/A
0.
36
1.0
6
1.0
4–
1.0
9
1.0
 ×
 10
–7
1.0
7
1.0
2–
1.1
1
2.
8 
× 
10
–3
1.0
6
1.0
4–
1.0
9
1.0
 ×
 10
–9
–8
.3
 ×
 10
–3
1.5
 ×
 10
–1
–2
.9
 ×
 10
–3
6.
2 
× 
10
–1
rs
72
62
62
15
N
C
_0
00
01
9.
9:
g.
46
29
41
36
G
>A
D
M
W
D
19
q1
3.
32
G
/A
0.
73
1.0
6
1.0
4–
1.0
9
1.7
 ×
 10
–6
1.1
1
1.0
5–
1.1
7
7.
3 
× 
10
–5
1.0
7
1.0
5–
1.1
0
1.7
 ×
 10
–9
4.
2 
× 
10
–3
4.
8 
× 
10
–1
–9
.0
 ×
 10
–3
1.2
 ×
 10
–1
rs
73
15
83
93
N
C
_0
00
02
2.
10
:g
.3
33
35
38
6C
>G
SY
N
3
22
q1
2.
3
C
/G
0.
74
1.0
6
1.0
4–
1.0
9
1.1
 ×
 10
–6
1.0
9
1.0
3–
1.1
4
1.4
 ×
 10
–3
1.0
7
1.0
5–
1.0
9
7.7
 ×
 10
–9
–1
.8
 ×
 10
–3
7.7
 ×
 10
–1
–5
.9
 ×
 10
–3
3.
3 
× 
10
–1
Th
is
 ta
bl
e 
sh
ow
s 
as
so
ci
at
io
n 
st
at
is
tic
s 
in
 U
K 
Bi
ob
an
k 
(2
1,0
81
 c
as
es
 a
nd
 17
9,
71
1 c
on
tr
ol
s)
, I
CG
C
 c
oh
or
ts
 (1
4,
65
4 
ca
se
s 
an
d 
42
,3
65
 c
on
tr
ol
s)
, t
he
 o
ve
ra
ll 
m
et
a-
an
al
ys
is
 (3
5,
73
5 
ca
se
s 
an
d 
22
2,
07
6 
co
nt
ro
ls
), 
an
d 
Sp
iro
M
et
a 
st
ud
ie
s 
(F
EV
1 a
nd
 F
EV
1/
FV
C
; n
 =
 7
9,
05
5)
. P
 v
al
ue
s 
ar
e 
tw
o 
si
de
d,
 b
as
ed
 o
n 
W
al
d 
st
at
is
tic
s 
(C
O
PD
) a
nd
 t 
st
at
is
tic
s 
(F
EV
1 a
nd
 F
EV
1/
FV
C
) w
ith
ou
t m
ul
tip
le
-c
om
pa
ris
on
 a
dj
us
tm
en
t. 
A
lt.
, a
lte
rn
at
e;
 R
A
F, 
ris
k 
al
le
le
 fr
eq
ue
nc
y;
 C
I, 
co
nf
id
en
ce
 in
te
rv
al
; O
R,
 o
dd
s 
ra
tio
; I
CG
C
, I
nt
er
na
tio
na
l C
O
PD
 G
en
et
ic
s 
Co
ns
or
tiu
m
; H
G
V
S,
 H
um
an
 G
en
om
e 
Va
ria
tio
n 
So
ci
et
y.
NATuRE GENETICS | VOL 51 | MARCH 2019 | 494–505 | www.nature.com/naturegenetics496
ArticlesNature GeNetics
interaction, co-regulation of gene expression with gene sets, and 
coding variant data (Fig. 3 and Methods).
At the 82 associated loci, 472 genes within 1 Mb of the top asso-
ciated variants were implicated by analysis of at least one dataset; 
106 genes were implicated by lung gene expression37,38, and an 
additional 50 genes were implicated by two or more other datasets 
(methylation39, chromatin interaction40, open chromatin regions41, 
similarity in gene sets42, or deleterious coding variants43; Fig. 3), for 
a total of 156 genes meeting more stringent criteria. Excluding loci 
in the MHC region, the median number of potentially implicated 
genes per locus was four, with a maximum of 17 genes (7q22.1 and 
17q21.1). The median distance of the implicated genes to the top 
associated variants was 346 kb. Of the 82 loci, 60 (73%) included the 
nearest gene among the implicated genes. We identified 20 genes 
with supportive evidence from exome-sequencing data. Two genes 
(ADAM19 and ADAMTSL3) were each implicated by five data-
sets (Fig. 3), and another two (EML4 and RIN3) were implicated 
by four datasets. A summary of all genes implicated by using these 
approaches is included in Supplementary Table 7.
Associated pathways. To gain further functional insight into the 
associated genetic loci, we performed gene-set enrichment analysis 
by using DEPICT42. Among the 165 enriched gene sets at a false-
discovery rate (FDR) <5%, 44% were related to the developmen-
tal process term, with a nominal P value for lung development of 
1.02 × 10−6; significant subterms included lung alveolus develop-
ment (P = 0.0003) and lung morphogenesis (P = 0.0005). We also 
found enrichment of extracellular-matrix-related pathways, includ-
ing laminin binding, integrin binding, mesenchyme development, 
cell–matrix adhesion, and actin filament bundles. Additional path-
ways of note included histone deacetylase binding, the Wnt-receptor 
signaling pathway, SMAD binding, the MAPK cascade, and the 
transmembrane receptor protein serine/threonine kinase signaling 
pathway. Full enrichment analysis results, including the top genes 
for each DEPICT gene set, are shown in Supplementary Table 8.
Identification of drug targets. GWAS is also useful for identifying 
drug targets at either the individual gene18,44,45 or genome-wide46,47 
level. Of the 472 candidate target genes, 59 genes were targeted by 
at least one approved or in-development drug48, for a total of 427 
drugs with 134 different modes of action (Supplementary Table 9). 
Druggable targets at new loci for COPD and lung function included 
ABHD6, CDKL2, GSTO2, KCNC4, PDHB, SLK, and TRPM7. We 
also identified drugs for repurposing in COPD by using transcrip-
tome-wide associations and drug-induced gene expression signa-
tures49 (Supplementary Note).
Phenotypic effects of COPD-associated variants. To characterize 
the phenotypic effects of the 82 genome-wide-significant loci, we 
performed a phenome-wide association analysis within the deeply 
phenotyped COPDGene study (Methods). We looked for common 
patterns of phenotype associations for the 82 loci by using hierarchi-
cal clustering across scaled z scores of phenotype–variant associa-
tions. We identified two clusters of variants differentially associated 
with two sets of phenotypes (Supplementary Fig. 4). Because these 
two variant–phenotype clusters appeared to be driven by computed 
tomography (CT) imaging features, we repeated variant cluster-
ing but limited analysis to quantitative CT imaging features. We 
again found two clusters of variants, differentiated by association 
with quantitative emphysema, emphysema distribution, gas trap-
ping, and airway phenotypes (Fig. 4a). Additionally, we evaluated 
the association of the 82 genome-wide-significant variants in a 
prior GWAS of emphysema and airway quantitative CT features50 
(Supplementary Table 10).
We also examined all genome-wide-significant loci in the NHGRI-
EBI GWAS Catalog51 (Supplementary Fig. 5 and Supplementary 
Table 11) and looked for trait-associated variants in LD (r2 > 0.2) 
with our lead COPD-associated variants. Many variants were associ-
ated with anthropometric measures including height and body mass 
index (BMI), measurements on blood cells (red and white blood 
cells), and cancers. COPD is well known to have many common 
comorbidities, such as coronary artery disease (CAD), type 2 diabe-
tes mellitus (T2D), osteoporosis, and lung cancer. Of these diseases 
and 13 additional traits, we confirmed previously reported overall 
genetic correlation (by using LD score regression52) of COPD with 
lung function, asthma, and height and found evidence of a modest 
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correlation between COPD and lung cancer (Supplementary Note). 
However, at individual loci and using a more stringent LD threshold 
(r2 > 0.6), we found evidence of shared risk factors for these comor-
bid diseases and COPD, including a genome-wide-significant vari-
ant near PABPC4 associated with T2D, four variants associated with 
CAD (near CFDP1, DMWD, STN1, and TNS1), and a variant near 
SPPL2C associated with bone density (Fig. 4b).
Overlapping loci with asthma and pulmonary fibrosis. On the 
basis of our previous identification of genetic overlap of COPD 
with asthma, and COPD with pulmonary fibrosis, we examined 
loci for overlap specifically with these two diseases. In asthma, we 
noted r2 >0.2 with one of our variants and previously reported vari-
ants at ID2, ZBTB38, C5orf56, MICA, AGER, HLA-DQB1, ITGB8, 
CLEC16A, and THRA. In pulmonary fibrosis, in addition to our 
previously described overlap at FAM13A, DSP, and 17q21, we noted 
overlapping associations at ZKSCAN1 and STN1 (Supplementary 
Table 12). To more closely examine overlap, we applied a Bayesian 
method (gwas-pw53) to COPD associations from our current 
GWAS and previous GWAS results for asthma (limited to those 
of European ancestry) and pulmonary fibrosis54,55. To mitigate the 
effects of including individuals with asthma among our COPD 
cases, we performed analysis for overlap with asthma after remov-
ing self-reported individuals with asthma from UK Biobank for this 
analysis (Methods). We identified 14 shared genome segments (pos-
terior probability >70%), 9 for asthma and 5 for pulmonary fibro-
sis (Fig. 4c and Supplementary Table 13). In addition to the three 
segments shared with pulmonary fibrosis identified in the previous 
study5 (FAM13A, DSP, and the 17q21 locus—here nearest CRHR1), 
we identified two new segments including loci near ZKSCAN1 and 
STN1 (formerly known as OBFC1). Shared variants for COPD and 
pulmonary fibrosis all had opposite directions of effect in the two 
diseases (that is, increasing risk for COPD but protective for pul-
monary fibrosis). In asthma, we identified five shared segments in 
the 6p21-22 region, as well as the segments containing ADAM19, 
ARMC2, ELAVL2, and STAT6. With the exception of the segment 
with STAT6, overlapping variants showed the same direction of 
effect.
Discussion
Genetic factors have an important role in COPD susceptibility. We 
examined genetic risk of COPD in a GWAS of 35,735 cases and 
222,076 controls. We identified 82 genome-wide-significant loci for 
COPD, of which 47 were previously identified in GWAS of COPD 
or population-based measures of lung function. Of the 35 loci not 
previously described at the time of analysis, 13 replicated in an inde-
pendent study of population-based lung function. We used several 
data sources to attempt to assign causal genes at each locus, iden-
tifying 156 genes at the 82 loci that were supported by either gene 
expression or a combination of at least two other data sources. Our 
results identify specific genes, cell types, and biological pathways 
for targeted study and also suggest a genetic basis for the clinical 
heterogeneity seen in COPD.
Our study supports a role for early life events in the risk of COPD. 
Gene-set enrichment analysis identified developmental pathways 
both specific to the lung (for example, lung morphogenesis and 
lung alveolar development) and related to the lung (for example, 
the canonical Wnt receptor56,57 and MAPK–ERK and nerve growth 
factor receptor signaling pathways). We also confirmed enrichment 
of heritability for epigenomic marks in the fetal lung. Our findings 
are consistent with epidemiological studies demonstrating that 
a substantial portion of the risk for COPD may develop in early 
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life: genetic variants may set initial lung function58 and patterns of 
growth58–60. Although further work will be needed to confirm the 
causal variants and genes affected by our variants, testing the role of 
these genes in lung-development-relevant mouse or ex vivo mod-
els—for example, determining whether perturbation of these genes 
changes proliferation and differentiation of lung epithelial progeni-
tors in induced pluripotent stem cell (iPSC)-derived alveolar type 
2 lung cells44—could provide experimental evidence for the role of 
these genes in early life susceptibility. Ultimately, the goal of this 
work would be to identify targets for or subsets of high-risk indi-
viduals early in the disease course or molecular candidates that may 
affect lung repair and regeneration61.
Apart from genes related to lung development, our analyses 
highlighted several genes and pathways already of interest in COPD 
therapy (including the COPD target/therapy relationships exempli-
fied by CHRM3/acetylcholine receptor inhibitors and the MAPK 
pathway/p38 inhibitors)—supporting the role of genetic analyses in 
finding therapeutic targets18,62—and newer genes that may inform 
future functional studies. We identified IL17RD (encoding IL-17 
receptor D) as a potential effector gene at the 3p14 locus. Numerous 
studies have examined the role of IL-17A in COPD63, and IL17RD 
can differentially regulate pathways employed by IL-17A64. CHIA 
(chitinase acidic) at 1p13.3, which encodes a protein that degrades 
chitin65, exhibits lung-specific expression66,67. CHIA variants have 
been associated with FEV168, asthma69–72, and acid mammalian 
chitinase activity71,73. We identified several potential effector genes 
related to extracellular matrix, cell adhesion, cell–cell interactions, 
and elastin-associated microfibrils74–76, some of which have previ-
ously been identified in studies of lung function15. These include 
integrin family members that mediate cell–matrix communication 
(for example, ITGA1, ITGA2, and ITGA877–79), an integrin-ligand-
encoding gene (NPNT80), and genes encoding matrix proteins 
(for example, MFAP2 and ADAMTSL3). ADAMTSL3 has a role 
in cell–matrix interactions related to assembly of fibrillin and 
microfibril biogenesis81–83, and of our candidate effector genes, it 
was supported by the greatest number of bioinformatic analyses. 
Recombinant forms of other ADAMTS-like proteins have shown 
evidence in experiments of promoting and enhancing fibrillin and 
microfibril deposition and assembly84,85. ADAMTSL3 may have a 
role in preventing emphysematous destruction of lung tissue by 
ADAMTS in COPD.
In addition to identifying the effector gene for a variant, knowing 
the effector cell type is critical for functional studies. We identified 
an overall enrichment of epigenomic marks in lung tissue and GI 
smooth muscle (also identified in studies of lung function16); respi-
ratory smooth muscle was absent from the analyzed datasets. We 
also performed analyses of single-cell data in an attempt to identify 
the specific lung cell types in which our top variants are potentially 
functioning. We found evidence for enrichment of several cell types, 
including but not limited to endothelial cells, alveolar type 2 cells, 
and basal-like cells. Each of these cell types has been postulated to 
have a role in the development of COPD86–88, and our data are con-
sistent with the likely heterogeneity of lung cell types contributing 
to COPD susceptibility. The lung comprises at least 40 different res-
ident cell types89, most of which were not distinctly represented in 
these datasets. Thus, while our findings support the investigation of 
specific cell types for further functional studies, they also highlight 
the need for profiling of lung-relevant cell types and locus-specific 
analyses.
Characterization of functional variant effects could lead to bet-
ter disease subtyping and more targeted therapy for COPD. Cluster 
analysis on hundreds of COPD-associated features in the more 
extensively phenotyped COPDGene cohort showed heterogeneous 
effects of genetic variants on COPD-related phenotypes, includ-
ing CT measurements of airway abnormalities and emphysema—
well-described sources of heterogeneity in COPD90–92. Analyzing 
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Fig. 4 | Effects on COPD-related and other phenotypes. a, Heat map of 
scaled CT quantitative imaging associations with the 34 genome-wide-
significant variants (known and replicated new associations) with at least 
nominal (P < 0.05) association with any CT imaging feature in COPDGene 
non-Hispanic white participants. Cluster 1 variants are more associated with 
airway imaging features, and cluster 2 variants are more associated with 
emphysema imaging features. Variants are referred to by the closest gene. 
b, Overlap of genome-wide-significant loci for COPD and select traits from 
the GWAS Catalog. c, Genome-wide overlapping results for COPD with 
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hundreds of diseases and traits in the GWAS Catalog, we identified 
overlapping associations with various diseases and traits in mul-
tiple organ systems, including comorbidities such as CAD, bone 
mineral density, and T2D. The COPD-associated PABPC4 locus 
was associated with T2D93 and C-reactive protein (CRP) levels94. 
Although a causal gene in this locus and its contribution to COPD 
are unknown, the association of this locus with T2D may suggest a 
shared disease pathway and drug targets. In sum, the identification 
of variable associations for COPD risk loci with subphenotypes and 
other diseases95,96 may have potential for more nuanced approaches 
to therapy for COPD. Overall, our phenotype, gene, and pathway 
analyses illustrate the utility of both searching for enrichment of 
genetic signals overall and performing more detailed identification 
of the effects of individual variants or groups of variants.
We performed additional specific analysis in two diseases that 
overlap with COPD, asthma and pulmonary fibrosis. Genome-
wide genetic correlation of COPD with asthma has previously been 
described5, but our analysis is, to our knowledge, the first to identify 
specific genetic segments shared by asthma and COPD. While the 
effects at most of these shared segments were concordant in direc-
tion, one of the segments of particular interest near STAT6 had 
opposite directions of effect in the two diseases. STAT6 has a role 
in helper T cell type 2–dependent inflammation and is activated by 
IL-4 and IL-1397. IL-13 in turn has been found at increased levels in 
asthmatic airways98 but at decreased levels in severe emphysema99. In 
pulmonary fibrosis, variants at all overlapping loci have an opposite 
direction of effect in comparison to COPD5. This observation raises 
the possibility that specific therapies for one disease could increase 
the risk for the other disease, which may be worth evaluating in 
treatment trials. The reasons why genetic effects are divergent in 
COPD and fibrosis are unclear, but these identified opposite effects 
could point to molecular switches that influence why some smok-
ers develop emphysema whereas others develop pulmonary fibro-
sis. Although pulmonary fibrosis is an uncommon disease and was 
specifically excluded in several of our COPD case–control cohorts, 
interstitial lung abnormalities are increasingly being recognized as a 
potential precursor to fibrosis, and an inverse relationship between 
these abnormalities and emphysema has previously been identi-
fied100. Mechanistically, some have hypothesized that divergent 
derangement of Wnt and Notch signaling pathways101 and mesen-
chymal cell fate102 may be responsible for the distinct development 
of these two diseases. We also describe an overlapping region at the 
STN1 (previously known as OBFC1) locus. STN1 has a role in telo-
mere maintenance103; shortened telomeres have been observed in 
both COPD and idiopathic pulmonary fibrosis (IPF)104,105, and rare 
genetic variants in the telomerase pathway have been implicated in 
both pulmonary fibrosis and emphysema—though with a concor-
dant direction of genetic risk effects in both diseases106.
Although our study is a large GWAS of COPD, individuals meet-
ing our criteria for COPD in UK Biobank may be different from 
those in other studies, especially with respect to smoking history. 
We used the same definition of COPD as in our previous analysis5, 
which included nonsmokers. Our use of prebronchodilator spirom-
etry to define COPD (allowing us to maximize sample size) as well 
as population-based measures of lung function for replication could 
bias our findings against variants that are only associated with more 
severe forms of COPD. We did not exclude other causes of airway 
obstruction such as asthma, noting that asthma frequently over-
laps with and is misdiagnosed in COPD107. We performed several 
additional analyses to determine whether our findings were driven 
by or markedly different as a result of smoking status, asthma, or 
use of pre- instead of postbronchodilator spirometry to define 
COPD. The results of these additional analyses did not indicate 
a substantial effect of these factors on our overall findings and, 
together with prior analyses5,16, suggest that bias due to these fac-
tors is likely to be small. However, our study was not designed to 
identify differences between subgroups, and we cannot rule out a 
role for studying more severe disease or disease subtypes. We note 
that the alpha-1 antitrypsin locus (SERPINA1) has been identi-
fied as genome-wide significant in smaller studies of emphysema 
and in smokers with severe COPD108. In the current study, the PiZ 
allele (NC_000014.8:g.94844947C>T, rs28929470) was associated 
with P = 2.2 × 10−5 by using moderate to severe cases (FEV1 <80% 
predicted) and with a smaller P value (1.4 × 10−6) in severe cases 
(FEV1 <50% predicted) despite a smaller sample size, a phenom-
enon that we have previously described11. Thus, despite the strong 
overlap of COPD with quantitative spirometry measures, new loci 
may be identified through studies of sufficiently large subsets of 
patients with COPD and with more specific and homogeneous 
COPD phenotypes. Given the suggestive evidence for replication 
using a related (but not identical) phenotype for additional new 
loci beyond the 13 meeting a Bonferroni-corrected threshold for 
significance, we chose to include all loci significant in discovery in 
subsequent analyses, recognizing that we probably included some 
false-positive associations. Our study focused on relatively com-
mon variants, predominantly in individuals of European ancestry; 
more detailed studies of rare variants, the human leukocyte anti-
gen (HLA) regions, and other ancestry groups are warranted, but 
broader multiancestry analyses are limited by the number of cases 
in currently available cohorts. Although COPD sex differences 
have been reported109, we did not identify significant sex-specific 
differences in the effect sizes of the 82 top variants. Future stud-
ies including more subjects and methodological advances may be 
needed to elucidate this.
The global burden of COPD is increasing. Our work found 
a substantial number of new loci for COPD and used multiple 
lines of supportive evidence to identify potential genes and path-
ways for both existing and new loci. Further investigation of the 
genetic overlap of COPD with other respiratory diseases and the 
phenotypic effects of top loci found new shared loci for asthma 
and IPF and suggested heterogeneity across COPD-associated loci. 
Together, these insights provide multiple new avenues for investi-
gation of the underlying biology and potential therapeutics in this 
deadly disease.
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Methods
Study populations. UK Biobank is a population-based cohort consisting of 
502,682 individuals8. To determine lung function, we used measures of FEV1 
and FVC derived from spirometry blow-volume time-series data, subjected to 
additional quality control based on ATS/ERS criteria110 (Supplementary Note). As 
in our previous study5, we defined COPD by using prebronchodilator spirometry 
according to modified GOLD criteria for moderate to very severe airflow 
limitation9: FEV1 less than 80% of the predicted value (using reference equations 
from Hankinson et al.111) and a ratio between FEV1 and FVC of less than 0.7. In 
agreement with our previous analyses and enrollment criteria for COPD case–
control datasets112, we did not exclude individuals on the basis of self-reported 
asthma. Genotyping was performed by using the Axiom UK BiLEVE array and 
the Axiom Biobank array (Affymetrix) and imputed to the Haplotype Reference 
Consortium (HRC) version 1.1 panel113.
We invited participants in the prior ICGC COPD GWAS to provide case–
control association results (with the exception of the 1958 British Birth Cohort, to 
avoid overlapping samples with the replication sample). ICGC cohorts performed 
case–control association analysis based on prebronchodilator measurements 
of FEV1 and FEV1/FVC, and cases were identified by using modified GOLD 
criteria, as above. Studies were imputed to 1000 Genomes reference panels. 
Detailed cohort descriptions and cohort-specific methods were previously 
published5 (Supplementary Note). All studies complied with all relevant ethical 
regulations. Ethical/regulatory boards approved the study protocol for each study 
(Supplementary Note). We obtained informed consent from all participating 
individuals.
On the basis of the strong genetic overlap of lung function and COPD5, we 
performed lookups of select significant variants for FEV1 and FEV1/FVC in the 
SpiroMeta consortium meta-analysis21. Briefly, SpiroMeta comprised a total of 
79,055 individuals from 22 studies imputed to either the 1000 Genomes Project 
Phase 1 reference panel (13 studies) or the HRC (9 studies). Each study performed 
linear regression adjusting for age, age2, sex, and height, by using rank-based 
inverse normal transforms, adjusting for population substructure by using 
principal components or linear mixed models, and performing separate analyses 
for ever- and never-smokers or using a covariate for smoking (for studies of related 
subjects). Genomic control was applied to individual studies, and results were 
combined by using a fixed-effects meta-analysis21.
Genome-wide association analysis. In UK Biobank, we performed logistic 
regression of COPD, adjusting for age, sex, genotyping array, smoking pack-years, 
ever-smoking status, and principal components of genetic ancestry. Association 
analysis was done by using PLINK 2.0 alpha114 (downloaded on 11 December 
2017) with Firth-fallback settings, using Firth regression when quasicomplete 
separation or regular-logistic-regression convergence failure occurred. We 
performed a fixed-effects meta-analysis of all ICGC cohorts and UK Biobank, 
using METAL (version 2010-08-01)115. We assessed population substructure and 
cryptic relatedness by LD score regression intercept10. We defined a genetic locus 
by using a 2-Mb window (±1 Mb) centered on a lead variant, with conditional 
analyses as described below.
To maximize our power to identify existing loci and discover new loci, we 
examined all loci at the genome-wide-significance value of P < 5 × 10−8. We first 
characterized loci as being previously described (evidence of prior association 
with lung function12–20,116,117 or COPD5,11,118) or new. We defined previously 
reported signals if they were in the same LD block in Europeans119 and in at least 
moderate LD (r2 ≥ 0.2) with previously described loci. For new loci, we attempted 
replication through association of each lead variant with either FEV1 or FEV1/
FVC ratio in SpiroMeta, using one-sided P values with Bonferroni correction for 
the number of new loci examined. New loci failing to meet a Bonferroni-corrected 
P-value threshold were assessed for nominal significance (one-sided P < 0.05) or 
directional consistency with FEV1 and FEV1/FVC ratio in SpiroMeta.
Cigarette smoking is the major environmental risk factor for COPD, and 
genetic loci associated with cigarette smoking have been reported5,120. While we 
adjusted for cigarette smoking in our analysis, we further examined these effects 
by additionally testing for association of each locus with cigarette smoking and 
by looking at two separate analyses of ever- and never-smokers in UK Biobank. 
We tested for sex-specific genetic effects of genome-wide-significant variants 
via a stratified analysis and interaction testing, using a 5% Bonferroni-corrected 
threshold to determine significance (Supplementary Note).
Identification of independent associations at genome-wide-significant loci. 
We identified specific independent associations at genome-wide-significant 
loci by using GCTA-COJO22. This method uses an approximate conditional 
and joint analysis approach requiring summary statistics and representative LD 
information. Because UK Biobank provided the predominant sample, we used 
10,000 randomly drawn unrelated individuals from this discovery dataset as an 
LD reference sample. We scaled genome-wide significance to a 2-Mb region, thus 
resulting in a locus-wide-significance threshold of 8 × 10−5, or 2 × 10−6 for variants 
in the MHC region (chr.6:28,477,797–33,448,354 in hg19). We created regional 
association plots via LocusZoom, using 1000 Genomes European (EUR) reference 
data121 (Nov2014 release).
Identification and prioritization of tissues and cell types, candidate variants, 
genes, and pathways. Identification of enriched tissues and specific cell types. We 
used LD score regression to estimate enrichment of functional annotations26 and 
specifically expressed gene regions31 on disease heritability. We used LD score 
regression baseline models (for example, conserved region or promoter-flanking 
region), tissue-specific annotations from the Roadmap Epigenomics Project31, 
integrated tissue annotations from GenoSkyline25, and cell-type-specific chromatin 
accessibility data27 (ATAC-seq). We used four single-cell gene expression (RNA-
seq) datasets to identify specific cell types (Supplementary Note), including (i) 
lung epithelial cells from normal and pulmonary fibrosis human lung28 (Gene 
Expression Omnibus (GEO) accession GSE86618), (ii) human iPSC-derived 
putative alveolar type 2 cells29 (GSE96642), and (iii) mouse lungs at embryonic 
day (E) 18.5 and (iv) mouse lungs at postnatal day (P) 1 from Whitsett et al. 
(unpublished; available at LungMAP30). We also used SNPsea32 to identify enriched 
cell types in genome-wide-significant loci (Supplementary Note). We report only 
estimates of coefficients and P values for the Roadmap annotations and gene 
expression datasets, because these analyses used –h2-cts, which does not report 
fold enrichment.
Fine-mapping of independent association signals at genome-wide-significant loci. 
We used Bayesian fine-mapping at each locus to identify the credible set—the set 
of variants with a 99% probability of containing a causal variant. Briefly, for each 
genome-wide-significant locus, we calculated the approximate Bayes factors33 of 
association. We then selected variants in each locus such that their cumulative 
posterior probability was greater than or equal to 0.99, by using unscaled variance. 
At loci with multiple independent associations, we used statistics from approximate 
conditional analysis with GCTA software on each index variant, adjusting for 
other independent variants in the locus. Otherwise, we used unconditioned 
statistics from our meta-analysis. Details on characterization of variant effects are 
summarized in the Supplementary Note.
Identification of target genes. We used several computational approaches with 
corresponding available datasets to identify target genes in genome-wide-
significant loci. We used two methods that used gene expression data: (i) 
S-PrediXcan and (ii) DEPICT. We used S-PrediXcan37 to identify genes with 
genetically regulated expression associated with COPD. We used data from 
the Lung-eQTL consortium38 (1,038 lung tissue samples) as an eQTL and gene 
expression reference database. S-PrediXcan tests for association between a trait 
and imputed gene expression by using summary statistics. Here we performed 
S-PrediXcan, using models for protein-coding genes ±1 Mb from the top 
associated variants at genome-wide-significant loci. We used DEPICT42 to 
prioritize genes from ‘reconstituted’ gene sets.
We also used additional information on gene regulation, including epigenetic 
data: (i) regulatory fine-mapping, (ii) mQTLs, and (iii) chromosome-conformation 
capture. We used regulatory fine-mapping (regfm41) to overlap 99%-credible 
interval variants at each GWAS locus with open chromatin regions, on the basis 
of DHSs. The DHS cluster accessibility state was then associated with gene 
expression levels (for 13,771 genes) from 22 tissues in the Roadmap Epigenomics 
Project41. Using both the 99%-credible interval and DHS overlap, as well as DHS 
state and transcript level association, regfm calculated a posterior probability of 
association for each gene ±1 Mb from the lead SNP at each GWAS locus. We also 
searched for overlapping mQTL data from lung tissue, as recently described39. To 
determine whether these signals colocalized (rather than being related owing to 
LD), we performed colocalization analysis between our GWAS loci and mQTLs in 
genome-wide-significant loci by using eCAVIAR122 (Supplementary Note). We also 
sought information from publicly available chromosome-conformation capture 
data40. We queried association statistics of chromatin contact (that is, long-range 
chromatin interactions) between top associated variants and gene promoters 
nearby in the lung (fetal lung fibroblast cell line (IMR90) and human lung tissue40) 
using HUGIn123. We retained only the strongest associations (that is, those with the 
smallest P values) for each cell line or primary cell type in the analysis.
Finally, we searched for signals from deleterious variants by querying the 
consequences of variants within 99%-credible sets containing fewer than 50 
variants (Supplementary Note). We also searched for rare coding variants, on the 
basis of exome-sequencing results in the COPDGene, Boston Early-Onset COPD 
(BEOCOPD), and International COPD Genetics Network (ICGN) studies, as 
previously described43. In brief, we performed exome sequencing on 485 severe 
COPD cases and 504 smoking-resistant controls from the COPDGene study and 
1,554 subjects ascertained through 631 probands with severe COPD from the 
BEOCOPD and ICGN studies. Details on statistical tests for single-variant and 
gene-based analyses are summarized in the Supplementary Note.
For each dataset described above, we used Bonferroni-corrected P values or a 
fixed posterior probability threshold to determine target genes at each locus. We 
report protein-coding genes ±1 Mb from a top associated variant. We restricted 
our search to genes from the GRCh37 server in biomaRt124 with updated HUGO 
Gene Nomenclature Committee (HGNC) names (downloaded from the HGNC 
database of human gene names on 7 June 2018). For each locus, we used a 5% 
Bonferroni-corrected threshold (that is, P < 0.05 divided by the number of genes 
at a locus) to determine significance for four data types: gene expression data, 
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chromatin-conformation capture data, co-regulation of gene expression, and 
exome-sequencing results. For two remaining datasets, we used a fixed posterior 
probability (of gene association with a GWAS locus) threshold of 0.1 for regfm 
and eCAVIAR. We considered genes that were implicated by gene expression 
or a combination of two or more other datasets (for example, methylation and 
chromatin-conformation capture data) as target genes.
Identification of pathways. To identify enriched pathways in COPD-associated 
loci, we performed gene-set enrichment analysis by using the reconstituted gene 
sets from DEPICT, as described above42. We defined significant gene sets using 
FDR <5%.
Identification of drug targets. We queried our target genes by using the Drug 
Repurposing Hub48. This resource contains comprehensive annotations of 
launched drugs, drugs in phases 1–3 of clinical development, previously approved 
and preclinical or tool compounds, curated by using publicly available sources (for 
example, ChEMBL and DrugBank) and proprietary sources. We performed drug–
gene expression similarity analysis49 (The Query), using a ranked gene set from a 
gene-based association test37 (Supplementary Note).
Effects on COPD-related and other phenotypes. COPD is a complex and 
heterogeneous disorder comprising different biological processes and specific 
phenotypic effects. In addition, many loci discovered by GWAS have pleiotropic 
effects. To identify these effects, we performed (i) identification of overlapping 
genetic loci with related disorders (asthma and pulmonary fibrosis); (ii) genetic 
association studies of our genome-wide-significant findings by using COPD-
related phenotypes, including a cluster analysis to identify groups of variants 
that might be acting via similar mechanisms; (iii) lookup of top variants in prior 
COPD-related quantitative CT imaging feature GWAS; (iv) lookup of associations 
with other diseases and traits by using the GWAS Catalog; and (v) estimation of the 
genetic correlation between COPD and other diseases and traits.
To identify overlapping loci between COPD and other respiratory disorders, 
we used gwas-pw53 to perform pairwise analysis of GWAS. This method searches 
for shared genomic segments119 by using an adaptive significance threshold, 
allowing detection of loci below genome-wide significance. We identified shared 
segments or variants by using a posterior probability of colocalization greater 
than 0.7 (ref. 53). We obtained GWAS summary statistics from previous studies 
of pulmonary fibrosis55 and asthma in Europeans54. For the overlap analysis of 
COPD with asthma, we examined the influence of inclusion of individuals with 
self-reported asthma on both the overlap of discrete GWAS loci (using gwas-pw) 
and genome-wide genetic correlation (using LD score regression) by performing 
these analyses in the meta-analysis of ICGC studies and UK Biobank (with 
individuals with asthma removed from cases in the latter instance). To assess 
heterogeneous effects of COPD susceptibility loci on COPD-related features 
(phenotypes), we evaluated associations of our genome-wide-significant SNPs with 
121 detailed phenotypes (for example, lung function, CT-imaging-derived metrics, 
biomarkers, and comorbidities) available for 6,760 COPDGene non-Hispanic 
white individuals. We calculated z scores for each SNP–phenotype combination 
relative to the COPD risk allele to create a SNP-by-phenotype z-score matrix. 
We tested each COPD-related phenotype with at least one nominally significant 
association with one of our genome-wide-significant COPD SNPs, thus leaving 
us with 107 phenotypes. We then oriented all z scores to be positive (according 
to the sign of the median z score) in association with each phenotype to avoid 
clustering based on the direction of association. To avoid clustering phenotypes 
only by strength of association with SNPs, we scaled the z scores within each 
phenotype by subtracting the mean z scores and dividing by the standard deviation 
of the z scores within each phenotype. We then scaled z scores across SNPs to 
circumvent clustering of SNPs according to only the relative strength of association 
with phenotypes. We then performed hierarchical clustering of the scaled z 
scores of associations between SNPs and phenotypes to identify clusters of SNPs 
and phenotypes for all 107 phenotypes as well as in the subset of 26 quantitative 
imaging phenotypes. We performed clustering of variants both in the set of all 
genome-wide-significant variants in discovery and in the subset of known variants 
plus new variants meeting a strict Bonferroni threshold in SpiroMeta replication 
(Supplementary Note). We further examined top variant associations with COPD-
related traits through lookup of top variants in a prior GWAS of 12,031 subjects 
with quantitative emphysema and airway CT features50. To examine the overlap 
of our COPD results with other traits, we downloaded genome-wide-significant 
associations from the GWAS Catalog51 (P < 5 × 10−8; downloaded on 10 April 
2018). We computed the LD for a pair of COPD- and trait-associated variants 
within the same LD block in Europeans119 by using the European-ancestry panel125 
and considered overlap to be present if variants were in at least moderate LD 
(r2 ≥ 0.2). We estimated genetic correlation between COPD and other diseases and 
traits by using a web engine for LDSC, LD Hub52. We assessed the results by using a 
5% Bonferroni-corrected significance level.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Genome-wide association summary statistics are available at the database of 
Genotypes and Phenotypes (dbGaP) under accession phs000179.v5.p2 and via 
the UK Biobank. Derived phenotypic data for COPD case–control status are also 
available from UK Biobank.
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Data collection We derived various metrics on spirometry quality control using R. Software for genotype imputation: IMPUTE2 (ARIC, CHS AA, KARE, 
MESA, SPIROMICS), minimac (CHS EUR, COPDGene, ECLIPSE, FHS, LifeLines, NETT-NAS, GenKOLS), MaCH (COPDGene, ECLIPSE, FHS, 
NETT-NAS, GenKOLS), and Michigan Imputation Server (eQTL).
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Data analysis We generated genome-wide summary statistics for UK Biobank using PLINK (v.2.0 alpha, https://www.cog-genomics.org/plink/2.0/). We 
performed a fixed-effects meta-analysis using METAL (v.2010-08-01, http://csg.sph.umich.edu/abecasis/Metal/download/). Regional 
association plots were generated using LocusZoom (v.1.4, https://github.com/statgen/locuszoom-standalone). We used LDSC (v.1.0, 
https://github.com/bulik/ldsc/) and SNPsea (v.1.0.3, https://github.com/slowkow/snpsea) to perform enrichment analysis of cell types. 
Fine-mapping was performed using Wakefield's method (v.2007-04-17, http://faculty.washington.edu/jonno/BFDP.R). We queried 
variant annotation using BioMart (v.2.36.1, http://www.biomart.org/) and HaploReg (v.4.1, http://archive.broadinstitute.org/mammals/
haploreg/haploreg.php). For target gene identification, we tested association of genetically regulated gene expression and COPD using S-
PrediXcan (v.0.6.1, https://github.com/hakyimlab/MetaXcan); colocalization analysis using eCAVIAR (v.2.1, https://github.com/fhormoz/
caviar); coding associations using SKAT (v.1.3.2.1, https://cran.r-project.org/package=SKAT), GESE (v.2.0.1, https://scholar.harvard.edu/
dqiao/gese), GMMAT (v.0.7, https://github.com/lin-lab/GMMAT), and MONSTER (v.1.3, http://www.stat.uchicago.edu/~mcpeek/
software/MONSTER/index.html); DNase hypersensitivity sites using regfm (v1.0.0, https://github.com/cotsapaslab/regfm); and 
reconstituted gene sets using DEPICT (v.140611, https://data.broadinstitute.org/mpg/depict/). We analyzed drug-gene expression 
signatures using the Query (https://clue.io). Other analyses were done using custom codes in R (v.3.5.0, https://www.r-project.org/).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers 
upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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The genome-wide association summary statistics is available at the database of Genotypes and Phenotypes (dbGaP) under accession phs000179.v5.p2 and via the 
UK Biobank. Derived phenotypic data for COPD case control status is also available in the UK Biobank.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size UK Biobank is a population-based cohort consisting of 502,682 individuals which was designed to detect genetic effect in multiple traits. The 
sample size calculation for each trait (e.g., COPD) was not pre-defined. For studies in International COPD Genetics Consortium (ICGC), most 
studies pre-determined the sufficient sample size according to their designs (e.g., case-control, population-based or family-based studies). 
Based on the post-hoc sample size calculation, the power to detect genetic association of COPD in UK Biobank was 1 (relative risk=1.1, minor 
allele frequency=0.3, COPD prevalence=0.1, Ncases=21081, Ncontrols=179713, significance=0.05).
Data exclusions The exclusion criteria were pre-established. For UK Biobank, we excluded samples based on 1) spirometry quality control (QC) 2) genotyping 
QC and 3) Genetic ancestry. Detailed descriptions of exclusion criteria were described in Supplementary Methods. Briefly, of 502,682 
individuals, 445,754 individuals had at least two measures of FEV1 and FVC and spirometry metrics, age, sex, height, and smoking. We 
included 324,299 individuals who had reproducible and acceptable measures of spirometry. For genotyping QC, we included 486,367 
individuals after excluding outlying heterozygosity or missingness, sex mismatch, >10 3rd degree relatives, and putative sex chromosome 
aneuploidy. We performed further analyses on individuals with European ancestry identified by K-means clustering.  For cohorts part of the 
International COPD Genetics Consortium, we removed subjects based on phenotype and genotype quality control as previously described. As 
in UK Biobank, we followed ATS/ERS guidelines for spirometry QC in ICGC studies. As in UK Biobank, ICGC studies followed ATS/ERS guidelines 
in performing the spirometry QC. We performed genotyping QC using the same rationale as in UK Biobank.
Replication After we identified novel genome-wide significant associations from the meta-analysis of COPD, we looked up their associations with FEV1 or 
FEV1/FVC in SpiroMeta, given the high genetic correlation of COPD and lung function. We determined significance in replication using a 
Bonferroni correction at 5% for a number of novel associations for COPD or lung function, requiring a consistent direction of effect (one-sided 
Bonferroni-corrected P value < 0.05). We also considered the nominal associations (P < 0.05) and directionally consistent associations. Of 35 
novel, 13 loci reached Bonferroni-corrected significance threshold (at P < 0.05) and 14 loci were nominally significant (P < 0.05) in the 
replication studies in the SpiroMeta. All 35 novel loci were directionally consistent. Loci failing to replicate may be due to the limited sample 
size in the SpiroMeta consortium.
Randomization This was observational study. Study individuals were not allocated to experimental groups.
Blinding Study individuals were not allocated to groups; blinding was not required.
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Population characteristics Characteristics of participants across 25 studies are described fully in Supplementary Table 1.  We included adult men and 
women, smokers and non-smokers.  Within the UK Biobank and the majority of the studies in the ICGC, we included individuals 
of European ancestry.  We tested for association between genetic variants and COPD adjusting for covariates including smoking 
status, and stratification by smoking status.
Recruitment Participants were recruited based on study design of each individual study (e.g., case-control, population-based, and family-
based studies). Informed consent was obtain for all participants and participants for each individual study were recruited in 
accordance with the standards of the committee or governing body with jurisdiction over human subjects research.
